Cargando…

Rare Case of Extracranial Metastases in a Patient with IDH-Mutant Glioblastoma

Glioblastoma are known for its aggressive intracranial course of disease, where the overall survival is less than 18 months. Of late, the World Health Organization has reclassified and renamed secondary glioblastomas as isocitrate dehydrogenase (IDH)-mutant grade 4 astrocytomas, which is relatively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thimma Sudarsan, Rishan, Ramanujan, Vishnu, Rajendran, Adhithyan, Shafi, Sadiya, Patil, Sushma, Ghosh, Siddhartha, Jalali, Rakesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635773/ https://www.ncbi.nlm.nih.gov/pubmed/37969678 http://dx.doi.org/10.1055/s-0042-1757425

Ejemplares similares

EPEN-22. Molecularly aggressive ependymomas treated with Image guided pencil beam proton therapy: consecutive patient Indian experience
por: Sudarsan, Rishan Thimma, et al.
Publicado: (2022)

Introduction of Proton Beam Therapy in Intracranial Germ Cell Tumors in India
por: Sudarsan, Rishan Thimma, et al.
Publicado: (2021)

Amide proton transfer imaging-arterial spin labeling mismatch: a new imaging biomarker for pilocytic astrocytoma
por: Rajendran, Adhithyan, et al.
Publicado: (2023)

Extracranial metastases in glioblastoma—Two case stories
por: Schou Nørøxe, Dorte, et al.
Publicado: (2018)

LINC-12. Encouraging early outcomes with image guided pencil beam proton therapy for cranio-spinal irradiation and unique considerations for paediatric population – First report from India
por: Gaikwad, Utpal, et al.
Publicado: (2022)

Extracranial metastases in secondary glioblastoma multiforme: a case report
por: Rossi, Jessica, et al.
Publicado: (2020)

Presentation of Two Cases with Early Extracranial Metastases from Glioblastoma and Review of the Literature
por: Johansen, Maria Dinche, et al.
Publicado: (2016)

Extracranial Metastases of a Cerebral Glioblastoma: A Case Report and Review of the Literature
por: Rosen, Jurij, et al.
Publicado: (2018)

Glioblastoma with extracranial parotid, lymph node, and pulmonary metastases: a case report
por: Swinnen, Jeroen, et al.
Publicado: (2019)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
por: Munjapara, Vasu, et al.
Publicado: (2022)

Extracranial metastases of anaplastic meningioma
por: Thomas, Robbin Zachery, et al.
Publicado: (2017)

Multiple extracranial metastases from glioblastoma multiforme: a case report and literature review
por: Liu, Jing, et al.
Publicado: (2020)

Molecular classification of IDH-mutant glioblastomas based on gene expression profiles
por: Wu, Fan, et al.
Publicado: (2019)

DNMT3A co-mutation in an IDH1-mutant glioblastoma
por: Fomchenko, Elena I., et al.
Publicado: (2019)

Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
por: Poon, Candice C., et al.
Publicado: (2019)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Successful Implementation of Image-Guided Pencil-Beam Scanning Proton Therapy in Medulloblastomas
por: Das, Anindita, et al.
Publicado: (2023)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

Paraneoplastic symptoms caused by extracranial meningioma metastases?
por: Mindermann, Thomas
Publicado: (2016)

Extracranial propagation of glioblastoma with extension to pterygomaxillar fossa
por: Tomac, Damir, et al.
Publicado: (2011)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping
por: Lyon, James F., et al.
Publicado: (2021)

Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
por: Jiang, Haihui, et al.
Publicado: (2021)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Extracranial Glioblastoma Metastasis: A Neuropathological Case Report
por: Stoyanov, George S, et al.
Publicado: (2023)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
por: Tejera, Dalissa, et al.
Publicado: (2020)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_phj8oviqt0f2bn8maad37nkq48